Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hCG pharmacological crossover study to improve anti-doping blood and urine testing
ACTRN12621001053819Phase 4Recruiting
- Sponsor
- Sydney Local Health District
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human chorionic gonadotrophin and human chorionic gonadotropin (2 arms), sponsored by Sydney Local Health District. Primary endpoint: Time course of serum and urine hCG concentrations. Started May 2022; status: recruiting.
02
Drugs
recombinant human chorionic gonadotrophinhuman chorionic gonadotropin
Beyond the preview
Go deeper on ACTRN12621001053819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001053819.